Cargando…
Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
Acute thrombotic thrombocytopenic purpura (aTTP) is a rare microangiopathic hemolytic anemia. Standard of care currently includes plasma exchange and immunosuppressive agents, including glucocorticoids, vincristine, and rituximab. Even with these therapies, relapse occurs in 36% of patients, and mor...
Autores principales: | Katsivalis, Katherine V., Thomas, Jamie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017799/ https://www.ncbi.nlm.nih.gov/pubmed/34109052 http://dx.doi.org/10.6004/jadpro.2021.12.2.8 |
Ejemplares similares
-
Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020) -
Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registry
por: Agosti, Pasquale, et al.
Publicado: (2023) -
Caplacizumab in adult patients with acquired thrombotic
thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020) -
Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020) -
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019)